The kallikreinkinin system in health and in diseases of the kidney

Kidney International

Volumn 75, Issue 10, 2009, Pages 1019-1030

  Kakoki, Masao ^a   Smithies, Oliver ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

ACE inhibitors; Aging; Bradykinin; DNA damage; Electron transport chain; Oxidative stress

Indexed keywords

ACETYLSALICYLIC ACID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BRADYKININ; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; CICAPROST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IBUPROFEN; INDOMETACIN; KALLIDIN; KALLIKREIN; KININ; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR;

ALPORT SYNDROME; AUTOSOMAL DOMINANT INHERITANCE; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG INHIBITION; GENE DELETION; GENE TARGETING; GLOMERULOSCLEROSIS; HUMAN; HYPERTENSION; KALLIKREIN KININ SYSTEM; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY POLYCYSTIC DISEASE; MITOCHONDRIAL RESPIRATION; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; OXIDATIVE STRESS; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RENAL DIABETES; REPERFUSION INJURY; REVIEW; SENESCENCE; TRANSCRIPTION REGULATION; URINARY EXCRETION; AGING; CELL RESPIRATION; PHYSIOLOGY;

AGING; CELL RESPIRATION; DIABETIC NEPHROPATHIES; HUMANS; KALLIKREIN-KININ SYSTEM; KIDNEY DISEASES;

EID: 67349177072     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.647     Document Type: Review

References (179)

1. Jaspard E, Wei L, Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem 1993; 268: 9496-9503.
2. Rigat B, Hubert C, Alhenc-Gelas F et al. An insertion/deletion polymorphismin the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346.
3. Lachurie ML, Azizi M, Guyene TT et al. Angiotensin-converting enzymegene polymorphism has no influence on the circulating reninangiotensin- aldosterone system or blood pressure in normotensive subjects. Circulation 1995; 91: 2933-2942.
4. Krege JH, Kim HS, Moyer JS et al. Angiotensin-converting enzyme gene mutations, blood pressures, and cardiovascular homeostasis. Hypertension 1997; 29(1 Part 2): 150-157.
5. Marre M, Bernadet P, Gallois Y et al. Relationships between angiotensin Iconverting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 1994; 43: 384-388.
6. Koh WP, Yuan JM, Sun CL et al. Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res 2003; 63: 573-578.
7. Gonzalez-Zuloeta Ladd AM, Vasquez AA, Sayed-Tabatabaei FA et al. Angiotensin-converting enzyme gene insertion/deletion polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14: 2143-2146.
8. Yaren A, Turgut S, Kursunluoglu R et al. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients with breast cancer and effects on prognostic factors. J Investig Med 2007; 55: 255-261.
9. Medeiros R, Vasconcelos A, Costa S et al. Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer. J Pathol 2004; 202: 330-335.
10. Yigit B, Bozkurt N, Narter F et al. Effects of ACE I/D polymorphism on prostate cancer risk, tumor grade and metastatis. Anticancer Res 2007; 27: 933-936.
11. Ebert MP, Lendeckel U, Westphal S et al. The angiotensin I-convertingenzyme gene insertion/deletion polymorphism is linked to early gastric cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 2987-2989.
12. Rocken C, Lendeckel U, Dierkes J et al. The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/deletion polymorphism. Clin Cancer Res 2005; 11: 2526-2530.
13. Farrer LA, Sherbatich T, Keryanov SA et al. Association between angiotensin-converting enzyme and Alzheimer disease. Arch Neurol 2000; 57: 210-214.
14. Li Y, Zagato L, Kuznetsova T et al. Angiotensin-converting enzyme I/D and alpha-adducin Gly460Trp polymorphisms: From angiotensin-converting enzyme activity to cardiovascular outcome. Hypertension 2007; 49: 1291-1297.
15. Raynolds MV, Bristow MR, Bush EW et al. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1073-1075.
16. Cambien F, Poirier O, Lecerf L et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-644.
17. Doi Y, Yoshinari M, Yoshizumi H et al. Polymorphism of the angiotensinconverting enzyme (ACE) gene in patients with thrombotic brain infarction. Atherosclerosis 1997; 132: 145-150.
18. Hamdi HK, Reznik J, Castellon R et al. Alu DNA polymorphism in ACE gene is protective for age-related macular degeneration. Biochem Biophys Res Commun 2002; 295: 668-672.
19. Huang W, Gallois Y, Bouby N et al. Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci USA 2001; 98: 13330-13334.
20. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23: 439-449.
21. Smithies O, Kim HS, Takahashi N et al. Importance of quantitative genetic variations in the etiology of hypertension. Kidney Int 2000; 58: 2265-2280.
22. Shesely EG, Hu CB, Alhenc-Gelas F et al. A second expressed kininogen gene in mice. Physiol Genomics 2006; 26: 152-157.
23. Skidgel RA, Engelbrecht S, Johnson AR et al. Hydrolysis of substance p and neurotensin by converting enzyme and neutral endopeptidase. Peptides 1984; 5: 769-776.
24. Hoang MV, Turner AJ. Novel activity of endothelin-converting enzyme: Hydrolysis of bradykinin. Biochem J 1997; 327(Part 1): 23-26.
25. Cayla C, Todiras M, Iliescu R et al. Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension. FASEB J 2007; 21: 1689-1698.
26. Schremmer-Danninger E, Offner A, Siebeck M et al. B1 bradykinin receptors and carboxypeptidase M are both upregulated in the aorta of pigs after LPS infusion. Biochem Biophys Res Commun 1998; 243: 246-252.
27. Spillmann F, Altmann C, Scheeler M et al. Regulation of cardiac bradykinin B1- and B2-receptor mRNA in experimental ischemic, diabetic, and pressure-overload-induced cardiomyopathy. Int Immunopharmacol 2002; 2: 1823-1832.
28. Griol-Charhbili V, Messadi-Laribi E, Bascands JL et al. Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. FASEB J 2005; 19: 1172-1174.
29. Duka I, Kintsurashvili E, Gavras I et al. Vasoactive potential of the b(1) bradykinin receptor in normotension and hypertension. Circ Res 2001; 88: 275-281.
30. Marin-Castano ME, Schanstra JP, Praddaude F et al. Differential induction of functional B1-bradykinin receptors along the rat nephron in endotoxin induced inflammation. Kidney Int 1998; 54: 1888-1898.
31. Couture R, Girolami JP. Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus. Eur J Pharmacol 2004; 500: 467-485.
32. Riad A, Zhuo JL, Schultheiss HP et al. The role of the renal kallikrein-kinin system in diabetic nephropathy. Curr Opin Nephrol Hypertens 2007; 16: 22-26.
33. Venema VJ, Ju H, Sun J et al. Bradykinin stimulates the tyrosine phosphorylation and bradykinin B2 receptor association of phospholipase C gamma 1 in vascular endothelial cells. Biochem Biophys Res Commun 1998; 246: 70-75.
34. Duchene J, Chauhan SD, Lopez F et al. Direct protein-protein interaction between PLCgamma1 and the bradykinin B2 receptor-importance of growth conditions. Biochem Biophys Res Commun 2005; 326: 894-900.
35. D'Orleans-Juste P, de Nucci G, Vane JR. Kinins act on B1 or B2 receptors to release conjointly endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells. Br J Pharmacol 1989; 96: 920-926.
36. Drummond GR, Cocks TM. Endothelium-dependent relaxations mediated by inducible B1 and constitutive B2 kinin receptors in the bovine isolated coronary artery. Br J Pharmacol 1995; 116: 2473-2481.
37. Zubakova R, Gille A, Faussner A et al. Ca2+ signalling of kinins in cells expressing rat, mouse and human B1/B2-receptor. Int Immunopharmacol 2008; 8: 276-281.
38. Hilgenfeldt U, Linke R, Riester U et al. Strategy of measuring bradykinin and kallidin and their concentration in plasma and urine. Anal Biochem 1995; 228: 35-41.
39. Liu X, Lukasova M, Zubakova R et al. Kallidin-like peptide mediates the cardioprotective effect of the ACE inhibitor captopril against ischaemic reperfusion injury of rat heart. Br J Pharmacol 2006; 148: 825-832.
40. Sangsree S, Brovkovych V, Minshall RD et al. Kininase I-type carboxypeptidases enhance nitric oxide production in endothelial cells by generating bradykinin B1 receptor agonists. Am J Physiol Heart Circ Physiol 2003; 284: H1959-H1968.
41. Pizard A, Blaukat A, Muller-Esterl W et al. Bradykinin-induced internalization of the human B2 receptor requires phosphorylation of three serine and two threonine residues at its carboxyl tail. J Biol Chem 1999; 274: 12738-12747.
42. Simaan M, Bedard-Goulet S, Fessart D et al. Dissociation of beta-arrestin from internalized bradykinin B2 receptor is necessary for receptor recycling and resensitization. Cell Signal 2005; 17: 1074-1083.
43. Enquist J, Skroder C, Whistler JL et al. Kinins promote B2 receptor endocytosis and delay constitutive B1 receptor endocytosis. Mol Pharmacol 2007; 71: 494-507.
44. Prabhakar P, Thatte HS, Goetz RM et al. Receptor-regulated translocation of endothelial nitric-oxide synthase. J Biol Chem 1998; 273: 27383-27388.
45. Wang DZ, Chao L, Chao J. Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. Hypertension 1997; 29(1 Part 2): 488-493.
46. Ni A, Yin H, Agata J et al. Overexpression of kinin B1 receptors induces hypertensive response to des-Arg9-bradykinin and susceptibility to inflammation. J Biol Chem 2003; 278: 219-225.
47. Milia AF, Gross V, Plehm R et al. Normal blood pressure and renal function in mice lacking the bradykinin B(2) receptor. Hypertension 2001; 37: 1473-1479.
48. Pesquero JB, Araujo RC, Heppenstall PA et al. Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc Natl Acad Sci USA 2000; 97: 8140-8145.
49. Kakoki M, McGarrah RW, Kim HS et al. Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proc Natl Acad Sci USA 2007; 104: 7576-7581.
50. Meneton P, Bloch-Faure M, Hagege AA et al. Cardiovascular abnormalitieswith normal blood pressure in tissue kallikrein-deficient mice. Proc Natl Acad Sci USA 2001; 98: 2634-2639.
51. Rhaleb NE, Yang XP, Nanba M et al. Effect of chronic blockade of the kallikrein-kinin system on the development of hypertension in rats. Hypertension 2001; 37: 121-128.
52. Schanstra JP, Duchene J, Praddaude F et al. Decreased renal NO excretion and reduced glomerular tuft area in mice lacking the bradykinin B2receptor. Am J Physiol Heart Circ Physiol 2003; 284: H1904-H1908.
53. Mayer B, Hemmens B. Biosynthesis and action of nitric oxide in mammalian cells. Trends Biochem Sci 1997; 22: 477-481.
54. Talukder MA, Fujiki T, Morikawa K et al. Up-regulated neuronal nitric oxide synthase compensates coronary flow response to bradykinin in endothelial nitric oxide synthase-deficient mice. J Cardiovasc Pharmacol 2004; 44: 437-445.
55. Harris MB, Ju H, Venema VJ et al. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J Biol Chem 2001; 276: 16587-16591.
56. Ju H, Venema VJ, Marrero MB et al. Inhibitory interactions of the bradykinin B2 receptor with endothelial nitric-oxide synthase. J Biol Chem 1998; 273: 24025-24029.
57. Harris MB, Ju H, Venema VJ et al. Role of heat shock protein 90 in bradykinin-stimulated endothelial nitric oxide release. Gen Pharmacol 2000; 35: 165-170.
58. Ignjatovic T, Stanisavljevic S, Brovkovych V et al. Kinin B1 receptors stimulate nitric oxide production in endothelial cells: signaling pathways activated by angiotensin I-converting enzyme inhibitors and peptide ligands. Mol Pharmacol 2004; 66: 1310-1316.
59. Savard M, Barbaz D, Belanger S et al. Expression of endogenous nuclear bradykinin B2 receptors mediating signaling in immediate early gene activation. J Cell Physiol 2008; 216: 234-244.
60. Ueno A, Ishida H, Oh-ishi S. Comparative study of endotoxin-induced hypotension in kininogen-deficient rats with that in normal rats. Br J Pharmacol 1995; 114: 1250-1256.
61. Lal MA, Kennedy CR, Proulx PR et al. Bradykinin-stimulated cPLA2 phosphorylation is protein kinase C dependent in rabbit CCD cells. Am J Physiol 1997; 273(6 Part 2): F907-F915.
62. Kennedy C, Proulx PR, Hebert RL. Bradykinin-induced translocation of cytoplasmic phospholipase A2 in MDCK cells. Can J Physiol Pharmacol 1997; 75: 563-567.
63. Libano-Soares JD, Gomes-Quintana E, Melo HK et al. B2 receptormediated dual effect of bradykinin on proximal tubule Na+ -ATPase: sequential activation of the phosphoinositide-specific phospholipase Cbeta/protein kinase C and Ca2+ -independent phospholipase A2 pathways. Biochim Biophys Acta 2008; 1778: 1316-1323.
64. Rodriguez JA, De la Cerda P, Collyer E et al. Cyclooxygenase-2 induction by bradykinin in aortic vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2006; 290: H30-H36.
65. Rodriguez JA, Vio CP, Pedraza PL et al. Bradykinin regulates cyclooxygenase-2 in rat renal thick ascending limb cells. Hypertension 2004; 44: 230-235.
66. Imig JD, Zhao X, Orengo SR et al. The bradykinin B2 receptor is required for full expression of renal COX-2 and renin. Peptides 2003; 24: 1141-1147.
67. Welsh C, Dubyak G, Douglas JG. Relationship between phospholipase C activation and prostaglandin E2 and cyclic adenosine monophosphate production in rabbit tubular epithelial cells. Effects of angiotensin, bradykinin, and arginine vasopressin. J Clin Invest 1988; 81: 710-719.
68. Liao JK, Homcy CJ. The G proteins of the G alpha i and G alpha q family couple the bradykinin receptor to the release of endothelium-derived relaxing factor. J Clin Invest 1993; 92: 2168-2172.
69. Dray A, Perkins M. Bradykinin and inflammatory pain. Trends Neurosci 1993; 16: 99-104.
70. Uknis AB, DeLa Cadena RA, Janardham R et al. Bradykinin receptor antagonists type 2 attenuate the inflammatory changes in peptidoglycan-induced acute arthritis in the Lewis rat. Inflamm Res 2001; 50: 149-155.
71. Hecker M, Bara AT, Bauersachs J et al. Characterization of endotheliumderived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals. J Physiol 1994; 481(Part 2): 407-414.
72. Campbell WB, Gebremedhin D, Pratt PF et al. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 1996; 78: 415-423.
73. Duchene J, Schanstra JP, Pecher C et al. A novel protein-protein interaction between a G protein-coupled receptor and the phosphatase SHP-2 is involved in bradykinin-induced inhibition of cell proliferation. J Biol Chem 2002; 277: 40375-40383.
74. Adler S, Huang H, Loke KE et al. Endothelial nitric oxide synthase plays an essential role in regulation of renal oxygen consumption by NO. Am J Physiol Renal Physiol 2001; 280: F838-F843.
75. Brown GC, Bolanos JP, Heales SJ et al. Nitric oxide produced by activated astrocytes rapidly and reversibly inhibits cellular respiration. Neurosci Lett 1995; 193: 201-204.
76. Sarti P, Lendaro E, Ippoliti R et al. Modulation of mitochondrial respiration by nitric oxide: investigation by single cell fluorescence microscopy. FASEB J 1999; 13: 191-197.
77. Brunori M, Giuffre A, Forte E et al. Control of cytochrome c oxidase activity by nitric oxide. Biochim Biophys Acta 2004; 1655: 365-371.
78. Lee I, Salomon AR, Ficarro S et al. cAMP-dependent tyrosine phosphorylation of subunit I inhibits cytochrome c oxidase activity. J Biol Chem 2005; 280: 6094-6100.
79. Piccoli C, Scacco S, Bellomo F et al. cAMP controls oxygen metabolism in mammalian cells. FEBS Lett 2006; 580: 4539-4543.
80. Mikrut K, Paluszak J, Kozlik J et al. The effect of bradykinin on the oxidative state of rats with acute hyperglycaemia. Diabetes Res Clin Pract 2001; 51: 79-85.
81. Golser R, Gorren AC, Leber A et al. Interaction of endothelial and neuronal nitric-oxide synthases with the bradykinin B2 receptor. Binding of an inhibitory peptide to the oxygenase domain blocks uncoupled NADPH oxidation. J Biol Chem 2000; 275: 5291-5296.
82. Kakoki M, Kizer CM, Yi X et al. Senescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors. J Clin Invest 2006; 116: 1302-1309.
83. Brunk UT, Terman A. Lipofuscin: mechanisms of age-related accumulation and influence on cell function. Free Radic Biol Med 2002; 33: 611-619.
84. Yumura W, Imasawa T, Suganuma S et al. Accelerated tubular cell senescence in SMP30 knockout mice. Histol Histopathol 2006; 21: 1151-1156.
85. Dimri GP, Lee X, Basile G et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92: 9363-9367.
86. Michikawa Y, Mazzucchelli F, Bresolin N et al. Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. Science 1999; 286: 774-779.
87. Tanhauser SM, Laipis PJ. Multiple deletions are detectable in mitochondrial DNA of aging mice. J Biol Chem 1995; 270: 24769-24775.
88. Gajewska M, Gajkowska B, Motyl T. Apoptosis and autophagy induced by TGF-B1 in bovine mammary epithelial BME-UV1 cells. J Physiol Pharmacol 2005; 56(Suppl 3): 143-157.
89. Kim KH, Park GT, Lim YB et al. Expression of connective tissue growth factor, a biomarker in senescence of human diploid fibroblasts, is upregulated by a transforming growth factor-beta-mediated signaling pathway. Biochem Biophys Res Commun 2004; 318: 819-825.
90. Sharma K, Ziyadeh FN. The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol 1994; 266(6 Part 2): F829-F842.
91. Tschope C, Seidl U, Reinecke A et al. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy. Int Immunopharmacol 2003; 3: 335-344.
92. Allard J, Buleon M, Cellier E et al. ACE inhibitor reduces growth factor receptor expression and signaling but also albuminuria through B2-kinin glomerular receptor activation in diabetic rats. Am J Physiol Renal Physiol 2007; 293: F1083-F1092.
93. Schafer S, Schmidts HL, Bleich M et al. Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent. Br J Pharmacol 2004; 143: 27-32.
94. Buleon M, Allard J, Jaafar A et al. Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model. Am J Physiol Renal Physiol 2008; 294: F1249-F1256.
95. Kakoki M, Takahashi N, Jennette JC et al. Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci USA 2004; 101: 13302-13305.
96. Yuan G, Deng J, Wang T et al. Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 50- monophosphate-activated protein kinase signaling pathways. Endocrinology 2007; 148: 2016-2026.
97. Tan Y, Keum JS, Wang B et al. Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy. Am J Physiol Renal Physiol 2007; 293: F1026-F1035.
98. Reyes AA, Karl IE, Kissane J et al. L-arginine administration prevents glomerular hyperfiltration and decreases proteinuria in diabetic rats. J Am Soc Nephrol 1993; 4: 1039-1045.
99. Kamijo H, Higuchi M, Hora K. Chronic inhibition of nitric oxide production aggravates diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty rats. Nephron Physiol 2006; 104: p12-p22.
100. Zhao HJ, Wang S, Cheng H et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 2006; 17: 2664-2669.
101. Mohan S, Reddick RL, Musi N et al. Diabetic eNOS knockout mice develop distinct macro- and microvascular complications. Lab Invest 2008; 88: 515-528.
102. Nakagawa T, Sato W, Glushakova O et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 2007; 18: 539-550.
103. Villa E, Rabano A, Ruilope LM et al. Effects of cicaprost and fosinopril on the progression of rat diabetic nephropathy. Am J Hypertens 1997; 10: 202-208.
104. Hirawa N, Uehara Y, Kawabata Y et al. Mechanistic analysis of renal protection by angiotensin converting enzyme inhibitor in Dahl saltsensitive rats. J Hypertens 1994; 12: 909-918.
105. Seccia TM, Belloni AS, Guidolin D et al. The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension. J Hypertens 2006; 24: 1419-1427.
106. Uehara Y, Hirawa N, Kawabata Y et al. Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats. Hypertension 1994; 24: 770-778.
107. Chao J, Li HJ, Yao YY et al. Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogenactivated protein kinase activity. Hypertension 2007; 49: 490-497.
108. Hirawa N, Uehara Y, Suzuki T et al. Regression of glomerular injury by kallikrein infusion in Dahl salt-sensitive rats is a bradykinin B2-receptormediated event. Nephron 1999; 81: 183-193.
109. Chao J, Zhang JJ, Lin KF et al. Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats. Kidney Int 1998; 54: 1250-1260.
110. Yayama K, Wang C, Chao L et al. Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension 1998; 31: 1104-1110.
111. Hutchison FN, Cui X, Webster SK. The antiproteinuric action of angiotensin-converting enzyme is dependent on kinin. J Am Soc Nephrol 1995; 6: 1216-1222.
112. Gross O, Beirowski B, Koepke ML et al. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 2003; 63: 438-446.
113. Gross O, Schulze-Lohoff E, Koepke ML et al. Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis. Nephrol Dial Transplant 2004; 19: 1716-1723.
114. Kaneto H, Morrissey J, McCracken R et al. Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney. Kidney Int 1994; 45: 1637-1647.
115. Ishidoya S, Morrissey J, McCracken R et al. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 1995; 47: 1285-1294.
116. Morrissey JJ, Ishidoya S, McCracken R et al. Nitric oxide generation ameliorates the tubulointerstitial fibrosis of obstructive nephropathy. J Am Soc Nephrol 1996; 7: 2202-2212.
117. Schanstra JP, Neau E, Drogoz P et al. In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 2002; 110: 371-379.
118. Bledsoe G, Crickman S, Mao J et al. Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. Nephrol Dial Transplant 2006; 21: 624-633.
119. Murakami H, Yayama K, Chao L et al. Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats. Kidney Int 1998; 53: 1305-1313.
120. Martinez-Salgado C, Eleno N, Tavares P et al. Involvement of reactive oxygen species on gentamicin-induced mesangial cell activation. Kidney Int 2002; 62: 1682-1692.
121. Ghaznavi R, Faghihi M, Kadkhodaee M et al. Effects of nitric oxide on gentamicin toxicity in isolated perfused rat kidneys. J Nephrol 2005; 18: 548-552.
122. Rivas-Cabanero L, Rodriguez-Barbero A, Arevalo M et al. Effect of NGnitro- L-arginine methyl ester on nephrotoxicity induced by gentamicin in rats. Nephron 1995; 71: 203-207.
123. Hsu YH, Chen CH, Hou CC et al. Prostacyclin protects renal tubular cells from gentamicin-induced apoptosis via a PPARalpha-dependent pathway. Kidney Int 2008; 73: 578-587.
124. Oosterlinck W, Roelandt R, De Sy WA et al. Captopril: a protective agent in renal warm ischemia in rats. Eur Urol 1985; 11: 36-39.
125. Kakoki M, Hirata Y, Hayakawa H et al. Effects of vasodilatory antihypertensive agents on endothelial dysfunction in rats with ischemic acute renal failure. Hypertens Res 2000; 23: 527-533.
126. Lopau K, Hefner L, Bender G et al. Haemodynamic effects of valsartan in acute renal ischaemia/reperfusion injury. Nephrol Dial Transplant 2001; 16: 1592-1597.
127. Pazoki-Toroudi HR, Hesami A, Vahidi S et al. The preventive effect of captopril or enalapril on reperfusion injury of the kidney of rats is independent of angiotensin II AT1 receptors. Fundam Clin Pharmacol 2003; 17: 595-598.
128. Liu YH, Yang XP, Sharov VG et al. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension 1996; 27: 7-13.
129. Kitakaze M, Minamino T, Node K et al. Beneficial effects of inhibition of angiotensin-converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs. Circulation 1995; 92: 950-961.
130. Guba M, Steinbauer M, Buchner M et al. Differential effects of short-term ace- and AT1-receptor inhibition on postischemic injury and leukocyte adherence in vivo and in vitro. Shock 2000; 13: 190-196.
131. Brookes PS, Yoon Y, Robotham JL et al. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J Physiol Cell Physiol 2004; 287: C817-C833.
132. Park SS, Zhao H, Mueller RA et al. Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3beta. J Mol Cell Cardiol 2006; 40: 708-716.
133. Chiang WC, Chien CT, Lin WW et al. Early activation of bradykinin B2 receptor aggravates reactive oxygen species generation and renal damage in ischemia/reperfusion injury. Free Radic Biol Med 2006; 41: 1304-1314.
134. Xia CF, Yin H, Borlongan CV et al. Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension 2004; 43: 452-459.
135. Koch M, Spillmann F, Dendorfer A et al. Cardiac function and remodeling is attenuated in transgenic rats expressing the human kallikrein-1 gene after myocardial infarction. Eur J Pharmacol 2006; 550: 143-148.
136. Matsumura Y, Nishiura M, Deguchi S et al. Protective effect of FK409, a spontaneous nitric oxide releaser, on ischemic acute renal failure in rats. J Pharmacol Exp Ther 1998; 287: 1084-1091.
137. Chintala MS, Chiu PJ, Vemulapalli S et al. Inhibition of endothelial derived relaxing factor (EDRF) aggravates ischemic acute renal failure in anesthetized rats. Naunyn Schmiedebergs Arch Pharmacol 1993; 348: 305-310.
138. Kakoki M, Hirata Y, Hayakawa H et al. Effects of tetrahydrobiopterin on endothelial dysfunction in rats with ischemic acute renal failure. J Am Soc Nephrol 2000; 11: 301-309.
139. Lifschitz MD, Barnes JL. Prostaglandin I2 attenuates ischemic acute renal failure in the rat. Am J Physiol 1984; 247(5 Part 2): F714-F717.
140. Tobimatsu M, Konomi K, Saito S et al. Protective effect of prostaglandin E1 on ischemia-induced acute renal failure in dogs. Surgery 1985; 98: 45-53.
141. Finn WF, Hak LJ, Grossman SH. Protective effect of prostacyclin on postischemic acute renal failure in the rat. Kidney Int 1987; 32: 479-487.
142. Tobimatsu M, Ueda Y, Saito S et al. Effects of a stable prostacyclin analog on experimental ischemic acute renal failure. Ann Surg 1988; 208: 65-70.
143. Paller MS, Manivel JC. Prostaglandins protect kidneys against ischemic and toxic injury by a cellular effect. Kidney Int 1992; 42: 1345-1354.
144. Braun C, Kleemann T, Birck R et al. Increased activity of the renal kallikrein-kinin system in autosomal dominant polycystic kidney disease in rats, but not in humans. Int Immunopharmacol 2002; 2: 1949-1956.
145. Kennefick TM, Al-Nimri MA, Oyama TT et al. Hypertension and renal injury in experimental polycystic kidney disease. Kidney Int 1999; 56: 2181-2190.
146. Ecder T, Chapman AB, Brosnahan GM et al. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2000; 35: 427-432.
147. Ecder T, Edelstein CL, Fick-Brosnahan GM et al. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol 2001; 21: 98-103.
148. Braun C, Kleemann T, Hilgenfeldt U et al. Activity and functional significance of the renal kallikrein-kinin-system in polycystic kidney disease of the rat. Kidney Int 2002; 61: 2149-2156.
149. Hostetter TH, Olson JL, Rennke HG et al. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981; 241: F85-F93.
150. MacLaughlin M, Monserrat AJ, Muller A et al. Role of kinins in the renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure. Kidney Blood Press Res 1998; 21: 329-334.
151. Wolf WC, Yoshida H, Agata J et al. Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney Int 2000; 58: 730-739.
152. Tu L, Xu X, Wan H et al. Delivery of recombinant adeno-associated virusmediated human tissue kallikrein for therapy of chronic renal failure in rats. Hum Gene Ther 2008; 19: 318-330.
153. Yamashita C, Tazawa N, Ohkita M et al. Exaggerated renal pathology of partial ablation-induced chronic renal failure in eNOS deficient mice. Biol Pharm Bull 2008; 31: 1029-1031.
154. Smithies O. Many little things: one geneticist's view of complex diseases. Nat Rev Genet 2005; 6: 419-425.
155. Maltais I, Bachvarova M, Maheux P et al. Bradykinin B2 receptor gene polymorphism is associated with altered urinary albumin/creatinine values in diabetic patients. Can J Physiol Pharmacol 2002; 80: 323-327.
156. Zanchi A, Moczulski DK, Hanna LS et al. Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int 2000; 57: 405-413.
157. Neugebauer S, Baba T, Watanabe T. Association of the nitric oxide synthase gene polymorphism with an increased risk for progression to diabetic nephropathy in type 2 diabetes. Diabetes 2000; 49: 500-503.
158. Harden PN, Geddes C, Rowe PA et al. Polymorphisms in angiotensinconverting- enzyme gene and progression of IgA nephropathy. Lancet 1995; 345: 1540-1542.
159. Yoshida H, Mitarai T, Kawamura T et al. Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995; 96: 2162-2169.
160. Baboolal K, Ravine D, Daniels J et al. Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in PKD1 adult polycystic kidney disease. Kidney Int 1997; 52: 607-613.
161. Perez-Oller L, Torra R, Badenas C et al. Influence of the ACE gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease. Am J Kidney Dis 1999; 34: 273-278.
162. Konoshita T, Miyagi K, Onoe T et al. Effect of ACE gene polymorphism on age at renal death in polycystic kidney disease in Japan. Am J Kidney Dis 2001; 37: 113-118.
163. Merta M, Reiterova J, Tesar V et al. Influence of the endothelial nitric oxide synthase polymorphism on the progression of autosomal dominant polycystic kidney disease and IgA nephropathy. Ren Fail 2002; 24: 585-593.
164. Lovati E, Richard A, Frey BM et al. Genetic polymorphisms of the reninangiotensin- aldosterone system in end-stage renal disease. Kidney Int 2001; 60: 46-54.
165. Gumprecht J, Zychma MJ, Grzeszczak W et al. Angiotensin I-converting enzyme gene insertion/deletion and angiotensinogen M235T polymorphisms: risk of chronic renal failure. End-Stage Renal Disease Study Group. Kidney Int 2000; 58: 513-519.
166. Bachvarov DR, Landry M, Pelletier I et al. Characterization of two polymorphic sites in the human kinin B1 receptor gene: altered frequency of an allele in patients with a history of end-stage renal failure. J Am Soc Nephrol 1998; 9: 598-604.
167. Zychma MJ, Gumprecht J, Zukowska-Szczechowska E et al. Polymorphisms in the genes encoding for human kinin receptors and the risk of end-stage renal failure: results of transmission/disequilibrium test. The End-Stage Renal Disease Study Group. J Am Soc Nephrol 1999; 10: 2120-2124.
168. Jozwiak L, Drop A, Buraczynska K et al. Association of the human bradykinin B2 receptor gene with chronic renal failure. Mol Diagn 2004; 8: 157-161.
169. Asakimori Y, Yorioka N, Yamamoto I et al. Endothelial nitric oxide synthase intron 4 polymorphism influences the progression of renal disease. Nephron 2001; 89: 219-223.
170. Wang Y, Kikuchi S, Suzuki H et al. Endothelial nitric oxide synthase gene polymorphism in intron 4 affects the progression of renal failure in non-diabetic renal diseases. Nephrol Dial Transplant 1999; 14: 2898-2902.
171. Westermann D, Schultheiss HP, Tschope C. New perspective on the tissue kallikrein-kinin system in myocardial infarction: role of angiogenesis and cardiac regeneration. Int Immunopharmacol 2008; 8: 148-154.
172. Daull P, Jeng AY, Battistini B. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases. J Cardiovasc Pharmacol 2007; 50: 247-256.
173. Desai AS, Swedberg K, McMurray JJ et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J Am Coll Cardiol 2007; 50: 1959-1966.
174. Ridings PC, Sugerman HJ, Blocher CR et al. Hemodynamic effects of bradykinin antagonism in porcine gram-negative sepsis. J Invest Surg 1995; 8: 115-122.
175. Abraham WM, Scuri M, Farmer SG. Peptide and non-peptide bradykinin receptor antagonists: role in allergic airway disease. Eur J Pharmacol 2006; 533: 215-221.
176. Griesbacher T, Rainer I, Tiran B et al. Kallikrein inhibitors limit kinin B(2) antagonist-induced progression of oedematous to haemorrhagic pancreatitis in rats. Br J Pharmacol 2008; 155: 865-874.
177. Levy JH, O'Donnell PS. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opin Investig Drugs 2006; 15: 1077-1090.
178. Blanchard A, Azizi M, Peyrard S et al. Partial human genetic deficiency in tissue kallikrein activity and renal calcium handling. Clin J Am Soc Nephrol 2007; 2: 320-325.
179. Picard N, Van Abel M, Campone C et al. Tissue kallikrein-deficient mice display a defect in renal tubular calcium absorption. J Am Soc Nephrol 2005; 16: 3602-3610.